Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...
For many life sciences start-ups, bringing on a GC early can be a strategic advantage. An experienced GC can help shape the ...
Senju Pharma has launched a new drug for dry eye disease (DED) in Japan, Avarept, which is the first drug in the TRPV1 ...
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs), developed by longtime ...
While positive, for rare disease it represents the first step of a much longer journey – one that will determine whether ...
The Beijing biotech has been set up to tap into the growing interest in macrocyclic peptides as an emerging treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results